CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
Top Cited Papers
- 3 March 2017
- journal article
- research article
- Published by Elsevier BV in European Urology
- Vol. 72 (6), 962-971
- https://doi.org/10.1016/j.eururo.2017.02.010
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted TherapyEuropean Urology, 2013
- Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 studyEuropean Journal Of Cancer, 2012
- Recommended confidence intervals for two independent binomial proportionsStatistical Methods in Medical Research, 2011
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Renal Cell Carcinoma in Adults 40 Years Old or Less: Young Age is an Independent Prognostic Factor for Cancer-Specific SurvivalEuropean Urology, 2007
- Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2004
- A POSTOPERATIVE PROGNOSTIC NOMOGRAM FOR RENAL CELL CARCINOMAJournal of Urology, 2001
- A Confidence Interval for the Median Survival TimePublished by JSTOR ,1982
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958